{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["103(2)"],"submitter":["Schmid C"],"pubmed_abstract":["No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213"],"journal":["Haematologica"],"pagination":["237-245"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5792268"],"repository":["biostudies-literature"],"pubmed_title":["Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation."],"pmcid":["PMC5792268"],"pubmed_authors":["Schmid C","Mufti G","Cornelissen JJ","Robin M","Beelen D","Arnold R","Finke J","Veelken H","Niederwieser D","Milpied N","de Witte T","Ehninger G","Gramatzki M","Maertens J","Yakoub-Agha I","Rovira M","van Biezen A","Volin L","Ganser A","Kanz L","Passweg J","Alessandrino P","de Wreede LC","Kroger N","Blaise D","Schleuning M"],"additional_accession":[]},"is_claimable":false,"name":"Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.","description":"No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Feb","modification":"2025-04-19T02:04:03.063Z","creation":"2019-07-24T07:12:39Z"},"accession":"S-EPMC5792268","cross_references":{"pubmed":["29101205"],"doi":["10.3324/haematol.2017.168716"]}}